C. Ola Landgren on Treating Smoldering Multiple Myeloma
C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses treating smoldering multiple myeloma.
C. Ola Landgren, MD, PhD, hematologic oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses treating smoldering multiple myeloma.
Smoldering multiple myeloma is an asymptomatic early precursor to multiple myeloma. Current guidelines recommend that patients with smoldering multiple myeloma be monitored, but studies have shown that early treatment can lead to rapid, durable responses, Landgren says.
Landgren adds that patients with high-risk smoldering multiple myeloma should be treated by myeloma specialists and consider enrolling in a clinical trial to delay or potentially prevent the development of multiple myeloma.
Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden
Published: March 19th 2025 | Updated: March 19th 2025Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.
